Aktiespot

Animalcare Group plc (ANIMALCARE GROUP PLC ORD 20P) Aktie

ANCR.L

Geschlossen
£331.500.00 (0.00%)
Chart wird geladen...

ANIMALCARE GROUP PLC ORD 20P

Eröffnung330.00
Hoch333.00
Tief330.00
Volumen36.24k
P/E47.36
Marktkapitalisierung228.89M
52-Wochen-Hoch340.00
52-Wochen-Tief216.00
Durchschn. Volumen385.77k
Dividende1.57%
Beta0.66
EPS0.07

Über Animalcare Group plc (ANIMALCARE GROUP PLC ORD 20P) Aktie

Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals for the companion animal, production animal, and equine veterinary markets in Europe, the Asia-Pacific, and internationally. It operates through Animalcare Europe and Randlab segments. The company offers Orozyme, an enzymatic toothpaste for dental care in cats and dogs; Danilon, an oral treatment for pain in horses; Dinalgen, an injectable treatment for pain in cattle, pigs, and horses; Aqupharm, a dehydration treatment for cats, dogs, cattle, goats, horses, pigs, rabbits, and sheep; Ulcershield, a treatment and prevention of gastric ulcers in horses; Daxocox, a treatment of osteoarthritis pain and inflammation in dogs; Plaqtiv+, a biofilm-based dental care for cats and dogs; Thiamacare, a treatment for hyperthyroidism in cats; Hemo, an injectable nutritional solution for horses; and Cosequin, a complementary feed for dogs and cats to strengthen and protect joints. It also provides nutritional supplements for the equine market; and professional support services to equine veterinarians. The company exports its products to approximately 45 countries. It has a collaboration with 272Bio to develop and commercialize a novel biological treatment for equine sweet itch. Animalcare Group plc is based in York, the United Kingdom.

Unternehmensinformationen

Börse: LSE (LSE)
Sektor: Sundhed
Branche: Lægemiddelproducenter – Special og generisk
Adresse:
Moorside
YO32 9LB York, United Kingdom
Telefon: + 44 1904 487 687

Analystenempfehlungen

Diese Übersicht gibt einen schnellen Einblick, wie Analysten das Aktienpotenzial basierend auf ihren neuesten Analysen und Kurszielen bewerten.

Niedrigstes Kursziel
336.00
1.4%
Durchschnittliches Kursziel
336.00
1.4%
Median Kursziel
336.00
1.4%
Höchstes Kursziel
336.00
1.4%

Andere sehen auch: